Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821487 | 1.00 | MAPK1 (0.46) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL2346041 | 0.83 | KDM4E (0.49) | MAPK1ATMKDM4EL3MBTL1POLB | |
| SCHEMBL29726958 | 0.82 | ALDH1A1 (0.51) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL473919 | 0.82 | ALDH1A1 (0.51) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL4538933 | 0.82 | MAPK1 (0.49) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL31444518 | 0.82 | MAPK1 (0.49) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL29220843 | 0.82 | KDM4E (0.50) | MAPK1ATMTDP1KDM4EL3MBTL1 | |
| SCHEMBL21702362 | 0.82 | TDP1 (0.42) | MAPK1TDP1L3MBTL1ALDH1A1KCNQ3 | |
| SCHEMBL20482099 | 0.82 | TDP1 (0.51) | MAPK1TDP1KDM4EL3MBTL1KMT2A | |
| SCHEMBL30047650 | 0.82 | TDP1 (0.42) | MAPK1TDP1L3MBTL1ALDH1A1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| CN-113072476-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-3911647-B1 | ISOXAZOLE COMPOUND AS FXR AGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| CN-101535265-A | Nicotinic acid derivatives as metabotropic glutamate receptor modulators | NOVARTIS AG (CH) | 2009-09-16 | — | — | CN | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| CN-101321731-A | Nicotinic acid derivatives as metabotropic glutamate receptor modulators | NOVARTIS AG (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1966144-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007071358-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | MAPK1 1335/4885ATM 3329/4885TDP1 3046/4885 |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | MAPK1 4344/4885ATM 4829/4885TDP1 2768/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | MAPK1 1186/4885ATM 3109/4885TDP1 2923/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | MAPK1 4362/4885ATM 4396/4885TDP1 4412/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | MAPK1 1736/4885ATM 3373/4885TDP1 4787/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | MAPK1 3987/4885ATM 4484/4885TDP1 2033/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | MAPK1 1736/4885ATM 3373/4885TDP1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.